
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

December 11, 2006
Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

000-50614
(Commission
File Number)

59-3410522
(IRS Employer
Identification No.)

**13700 Progress Boulevard
Alachua, Florida 32615**
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.02 Termination of a Material Definitive Agreement.

On December 11, 2006, the Company issued a press release announcing that it had met the conditions for early redemption of warrants issued in connection with its December 2005 private financing and had notified the holders of the warrants that the Company had exercised its right under the warrant to accelerate the expiration date of the warrants to January 8, 2007. The early expiration was triggered by the Company's stock price being above \$1.20 per share for 15 consecutive days. In the interim the warrant holders are entitled to exercise the warrant and acquire Company common stock at a warrant exercise price of \$0.60 per share, but must act by January 8, 2007. A total of approximately 1.4 million shares of Company common stock are able to be acquired pursuant to the outstanding warrants that are subject to the accelerated expiration notice. A copy of the press release announcing the expiration of the warrants is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01 Other Events.

On December 11, 2006, the Company highlighted recent events in a press release which had been previously reported. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Information and Exhibits.**(d) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated December 11, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 14, 2006**ORAGENICS, INC.
(Registrant)**

BY: /s/ Robert T. Zahradnik
Robert T. Zahradnik
President and Chief Executive Officer

Oragenics Calls Outstanding Warrants from December 2005 Private Financing Round**FOR IMMEDIATE RELEASE**

ALACHUA, FL (December 11, 2006) – Oragenics, Inc. (AMEX:ONI) announced today that it had met the conditions for early redemption of warrants associated with its December 2005 private financing round, and has issued notification to holders that the company has exercised its right to accelerate the expiration date. Warrant holders are entitled to purchase warrant shares from Oragenics at an exercise price of \$0.60 per share, but must now act by January 8, 2007. A total of approximately 1.4 million shares of Oragenics' common stock is involved in this accelerated redemption call.

Dr. Robert Zahradnik, Oragenics' president and CEO stated, "I would like to thank shareholders for participating in last year's financing that generated the warrants. Our company has had some important breakthroughs since the December 2005 placement, which, I believe, have added significant value for our shareholders." In 2006, Oragenics successfully tested its novel antibiotic, MU1140™, against *Staphylococcus aureus* in an infectious animal model, received its fourth patent for this technology, and determined that MU1140 kills bacteria by a novel mechanism, as was reported in the prestigious journal, *Science*. If animal toxicity studies are successful in Q1 2007, the company will petition the FDA to begin clinical trials. During 2006, international patent applications were filed to protect its anti-obesity agent, LPT3-04™, and its unique gene targets, identified with the company's proprietary IVIAT™ technology, for use in diagnosing and potentially preventing tuberculosis, a major global health threat. Oragenics continued to work with the FDA this year regarding clinical testing of the SMaRT Replacement Therapy™, and has successfully completed a pivotal human trial with its second dental product, Probiora3™ mouthrinse, which is now the subject of an active licensing campaign. In early 2006, Oragenics formed an International Scientific Advisory Board, composed of five past Chief Dental Officers, that has been instrumental in designing global clinical trials and identifying potential partners for our two oral care technologies. Our scientists also received a National Science Foundation grant this year to develop the company's patent pending DPOLT™ technology for synthesizing novel antibiotic peptides. Finally, Oragenics recently completed the acquisition of the iviGene Corporation, which brings in-house two powerful technologies for identifying genetic markers that can potentially serve as the basis for the next generation of diagnostic tests and therapies against the growing threats of drug-resistant infectious diseases and multiple forms of cancer. Dr. Zahradnik added, "It appears that additional investors have noticed Oragenics and its accomplishments over this past year, and I greatly appreciate the confidence and support that these new shareholders have shown for the company."

Additional funding will be necessary to further exploit the opportunities described above and to continue the Company's operations in the future. Management is hesitant at this time to issue additional equity at current valuations. However, if all of the outstanding warrant shares are purchased by January 8, 2007, and these funds are combined with existing cash, the company will have its highest cash position in the past eighteen months. On a fully diluted basis, the exercise of these warrants will cause no additional dilution to current shareholders and should provide sufficient funding, reduced by a current monthly burn rate of approximately \$150,000, to last through Q3 2007.

About Orogenics

Orogenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Orogenics' core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Orogenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to fund our future operations and successfully develop and commercialize products using the iviGene proprietary technologies and those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Orogenics, Inc.
Robert T. Zahradnik, 386-418-4018 X222
www.orogenics.com